Fan Zhenyi, Hu Zhizhou, Han Weiwei, Lu Xiaoxiong, Liu Xiaoxia, Zhou Min, Yan Wang, Wu Yunqin
Department of Neurology, Hwa Mei Hospital, University of Chinese Academy of Science, Ningbo, China.
Ningbo Institute of Life and Health Industry, University of Chinese Academy of Science, Ningbo, China.
Front Neurol. 2022 Mar 14;13:841677. doi: 10.3389/fneur.2022.841677. eCollection 2022.
Otolin-1 is an inner ear-specific protein that is exclusively expressed in otoconia and vestibule and cochlea cells. Recent investigations reported that otolin-1 can cross the blood-labyrinthine barrier and that the levels in serum well-reflected otolith status. Serum otolin-1 levels in patients with benign paroxysmal positional vertigo (BPPV) are significantly elevated compared with healthy controls. We aimed to explore whether otolin-1 can also serve as a biomarker for predicting BPPV recurrence.
Patients at our institution with new-onset of idiopathic BPPV between May, 2017 and May, 2018 were recruited and followed up for 2 years. All demographic data of the patients were collected, and serum levels of otolin-1 and other laboratory indicators were measured and compared according to the recurrence status.
A total of 74 patients, who met the inclusion criteria were enrolled in this study, of which 27 (36.5%) patients had suffered one or more episodes of recurrence after undergoing canal repositioning treatments during the study. The serum levels of otolin-1 in patients with recurrent BPPV were significantly higher than those in patients without recurrent BPPV (363.9 vs. 309.8 pg/ml, = 0.001). In multivariate analysis comparing the second to fourth quartiles (Q2-Q4) against the first quartile (Q1) of otolin-1, the level of otolin-1 in Q4 could significantly predict BPPV recurrence, and the odds ratio (OR) was elevated by approximately 812% (OR = 9.12; 95% confidence interval [CI]: 1.44-57.9; = 0.019).
High serum levels of otolin-1 were associated with an increased risk of BPPV recurrence, and further investigation is required to confirm this association and clarify the exact mechanism.
Otolin-1是一种内耳特异性蛋白，仅在内耳石、前庭和耳蜗细胞中表达。最近的研究报道，Otolin-1可穿过血迷路屏障，血清中其水平能很好地反映耳石状态。与健康对照相比，良性阵发性位置性眩晕（BPPV）患者血清Otolin-1水平显著升高。我们旨在探讨Otolin-1是否也可作为预测BPPV复发的生物标志物。
招募我院2017年5月至2018年5月新发特发性BPPV患者并随访2年。收集患者所有人口统计学数据，并根据复发状态测量和比较血清Otolin-1水平及其他实验室指标。
本研究共纳入74例符合纳入标准的患者，其中27例（36.5%）患者在研究期间接受半规管复位治疗后复发一次或多次。复发BPPV患者的血清Otolin-1水平显著高于未复发BPPV患者（363.9 vs. 309.8 pg/ml，P = 0.001）。在多因素分析中，将Otolin-1的第二至第四四分位数（Q2-Q4）与第一四分位数（Q1）进行比较，Q4水平的Otolin-1可显著预测BPPV复发，比值比（OR）升高约812%（OR = 9.12；95%置信区间[CI]：1.44-57.9；P = 0.019）。
血清Otolin-1水平升高与BPPV复发风险增加相关，需要进一步研究以证实这种关联并阐明确切机制。
